Synopsis of recent research by authors named "Hazel Manacsa"
- Hazel Manacsa's recent research focuses on the effects of dual renin-angiotensin-aldosterone system (RAAS) inhibition in patients with diabetic kidney disease (DKD), particularly examining its association with acute kidney injury (AKI) and hyperkalemia.
- The systematic review and meta-analysis reveals that while dual RAAS blockade may theoretically provide enhanced therapeutic effects, it is linked to a higher risk of AKI and hyperkalemia without demonstrating significant advantages in mortality rates, cardiovascular events, or the progression of chronic kidney disease.
- The findings emphasize caution in the clinical application of dual RAAS inhibition for managing DKD, suggesting that current monotherapy with RAAS inhibitors may be a safer and more beneficial approach for patients.
